Clinical trial
A Phase 2 Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib for Patients Whose Tumors Harbor Pathogenic Alterations in BRAF, RAF1, MEK1/2, ERK1/2, and NF1.
NCT04534283 is registered in ClinicalTrials.gov with Anita Turk as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib for Patients Whose Tumors Harbor Pathogenic Alterations in BRAF, RAF1, MEK1/2, ERK1/2, and NF1.
- Lead sponsor
- Anita Turk
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- October 5, 2020
- Completion date
- August 7, 2023
- Enrollment
- 16 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
braf v600e, cancer, cancer metastatic, erk mutation, mek1 gene mutation, mek2 gene mutation, raf1 gene mutation